The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario by Djalalov, S, Graham, D.M, Beca, J, Hoch, J.S, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (On... by Djalalov, S, Beca, J, Hoch, J.S, Krahn, M.D, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario by Djalalov, S, Hoch, J.S, Beca, J, Krahn, M, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario by Lim, C, Sekhon, H S, Cutz, J C, Hwang, D M, Kamel-Reid, S, Carter, R F, Santos, G da Cunha, Waddell, T, Binnie, M, Patel, M, Paul, N, Chung, T, Brade, A, El-Maraghi, R, Sit, C, Tsao, M S, Leighl, N B

Get full text

Crizotinib inhibition of ROS1- positive tumours in advanced non-small-cell lung cancer: a Canadian perspective by Bebb, D G, Agulnik, J, Albadine, R, Banerji, S, Bigras, G, Butts, C, Couture, C, Cutz, J C, Desmeules, P, Ionescu, D N, Leighl, N B, Melosky, B, Morzycki, W, Rashid-Kolvear, F, Lab, Clin, Sekhon, H S, Smith, A C, Stockley, T L, Torlakovic, E, Xu, Z, Tsao, M S

Get full text

Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? by VanderMeer, R, Chambers, S, Van Dam, A, Cutz, J C, Goffin, J R, Ellis, P M

Get full text

PCN128 - The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario by Djalalov, S., Graham, D.M., Beca, J., Hoch, J.S., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

PCN105 - Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded S... by Djalalov, S., Beca, J., Hoch, J.S., Krahn, M.D., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

PCN82 - Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario by Djalalov, S., Hoch, J.S., Beca, J., Krahn, M., Tsao, M.S., Cutz, J.C., Leighl, N.

Get full text

OP09.08: Correlation between ultrasound, x‐ray and CT scan with histopathology in antenatally diagnosed cases of congenital pulmonary airway malformation (CPAM) by Mehta, S., Al‐Ibrahim, A., Mittal, A., O'Brien, K., Unger, S., Seaward, G., Windrim, R., Langer, J.C., Chiu, P., Cutz, E., Ryan, G.

Get full text

OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study by Tammemägi, M., Schmidt, H., Martel, S., Mcwilliams, A., Goffin, J., Johnston, M., Goss, G., Tremblay, A., Bhatia, R., Liu, G., Soghrati, K., Yasufuku, K., Hwang, D., Laberge, F., Gingras, M., Pasian, S., Couture, C., Mayo, J.R., Fauerbach, P.V. Nasute, Atkar-Khattra, S., Peacock, S.J., Cressman, S., Ionescu, D., English, J.C., Finley, R.J., Yee, J., Puksa, S., Stewart, L., Tsai, S., Haider, E., Boylan, C., Cutz, J., Manos, D., Xu, Z., Nicholas, G., Seely, J.M., Amjadi, K., Sekhon, H.S., Burrowes, P., Maceachern, P., Urbanski, S., Sin, D., Tan, W.C., Leighl, N., Shepherd, F., Evans, W., Tsao, M., Lam, S.

Get full text

Pulmonary neuroendocrine cells in neonatal rats with congenital diaphragmatic hernia by Ijsselstijn, H., Perrin, D.G., de Jongste, J.C., Cutz, E., Tibboel, D.

Get full text